IMU-838 22.5 mg tablet
Sponsors
Goethe University Frankfurt, Immunic AG
Conditions
Post Covid Syndrome (PCS)Progressive forms of Multiple SclerosisRelapsing-remitting multiple sclerosis
Phase 2
Randomized adaptive assessment of post COVID syndrome
treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome
(REVIVE)
CompletedCTIS2024-511628-16-00
Start: 2024-07-18End: 2025-09-30Target: 376Updated: 2025-05-09
P2-IMU-838-MS - Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsingremitting multiple sclerosis (RRMS) (EMPhASIS)
RecruitingCTIS2024-516739-29-00
Start: 2019-01-23Target: 142Updated: 2025-04-03
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
RecruitingCTIS2024-514617-35-00
Start: 2021-12-20Target: 230Updated: 2025-04-03